Baghdadi Leena R, Alhassan Mohammed K, Alotaibi Fawaz H, Alsuwaida Anas A, Shehadah Ali E, Alzahrani Mohammed T
Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Front Psychiatry. 2023 Jun 6;14:1184720. doi: 10.3389/fpsyt.2023.1184720. eCollection 2023.
Rheumatoid arthritis (RA) can cause depression and anxiety. This study evaluated the factors associated with depression and anxiety in patients with RA and examined the effect of conventional and biologic disease-modifying antirheumatic drugs (DMARDs).
This cross-sectional study was conducted in a regional hospital in Riyadh between March and November 2022 and included 213 patients with RA. Depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS) and data about patients' DMARDs use was obtained from the hospital's medical records.
Based on the HADS scores, 35 (16.4%) and 49 (23%) patients with RA had depression and anxiety, respectively. There was a significant association between the level of depression and anxiety and the use of leflunomide and tocilizumab among patients with RA ( = 0.006 and = 0.009, respectively). Patients with RA who took leflunomide had significantly higher scores for anxiety ( = 0.158, value of = 0.037) when compared to patients who did not take leflunomide. Patients with RA who took etanercept showed a significantly lower depression score even after adjusting for confounders, including sociodemographic, clinical, and lifestyle factors ( = -0.189, = 0.043).
The present study highlighted the prevalence of psychiatric disorders among patients with RA and the level of depression and anxiety may differ between patients with RA depending on the type of DMARDs used. We recommend patients with RA be screened regularly for depression and anxiety to avoid further extra-articular systemic complications associated with RA.
类风湿关节炎（RA）可导致抑郁和焦虑。本研究评估了RA患者中与抑郁和焦虑相关的因素，并考察了传统和生物改善病情抗风湿药物（DMARDs）的作用。
本横断面研究于2022年3月至11月在利雅得的一家地区医院进行，纳入了213例RA患者。使用医院焦虑抑郁量表（HADS）测量抑郁和焦虑情况，并从医院病历中获取患者使用DMARDs的数据。
根据HADS评分，分别有35例（16.4%）和49例（23%）RA患者存在抑郁和焦虑。RA患者中抑郁和焦虑水平与来氟米特和托珠单抗的使用之间存在显著关联（分别为 = 0.006和 = 0.009）。与未使用来氟米特的RA患者相比，使用来氟米特的RA患者焦虑得分显著更高（ = 0.158， = 0.037）。即使在对包括社会人口统计学、临床和生活方式因素在内的混杂因素进行调整后，使用依那西普的RA患者抑郁得分仍显著更低（ = -0.189， = 0.043）。
本研究强调了RA患者中精神障碍的患病率，并且根据所使用的DMARDs类型，RA患者的抑郁和焦虑水平可能有所不同。我们建议对RA患者定期进行抑郁和焦虑筛查，以避免与RA相关的进一步关节外全身并发症。
